Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04268498 · ClinicalTrials.gov registry record · Phase 2
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by University of Miami.
- Active
- Registry status
- Phase 2
- Development phase
- 310
- Enrollment target
- 7
- Study locations
NCT04268498: Active Phase 2 study of Multiple Myeloma, sponsored by University of Miami.
NCT04268498 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by University of Miami. The registered enrollment target is 310 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (43% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04268498, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by University of Miami.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 310 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the standard of care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).
Primary Outcome
MRD will be assessed by the MRD scale ranging from 10 (increased disease detection) to -5 (less to no disease detection) after 8 cycles of therapy.
Conditions Studied
Interventions
- DRUG Acetaminophen
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Diphenhydramine
- DRUG Bortezomib
Study Locations (7)
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
- Stony Brook University - Stony Brook
Florida
- University of Miami - Miami
- Moffitt Cancer Center - Tampa
Texas
- MD Anderson Cancer Center - Houston
Utah
- Huntsman Cancer Institue - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2020-02-11 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 2 |
What the registry record for NCT04268498 still lists
NCT04268498 is an interventional study that assigns participants to a tested intervention. The registered 310 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Acetaminophen is the first listed.
NCT04268498 lists 7 locations in 4 states (New York, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT04268498 about?
NCT04268498 is a clinical study titled "A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma". This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the standard of care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).
What is the current status of trial NCT04268498?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 310 participants. The study started on 2020-02-11. Estimated completion is 2027-02-01.
What conditions does trial NCT04268498 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04268498?
The interventions under investigation include: Acetaminophen (DRUG), Dexamethasone (DRUG), Lenalidomide (DRUG), Diphenhydramine (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT04268498?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04268498 being conducted?
This trial has 7 study locations across Florida, New York, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04268498's enrollment target sits among peer trials
310 71st of 438 higher than 368 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
- NCT04878094 · 310 participants · Phase 3
A Study of Intra-operative Imaging in Women With Ovarian Cancer
- NCT05459233 · 310 participants · NA
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI